| 1.555 0.145 (10.28%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.35 | 1-year : | 3.48 |
| Resists | First : | 2.01 | Second : | 2.98 |
| Pivot price | 1.27 |
|||
| Supports | First : | 0.45 | Second : | 0.37 |
| MAs | MA(5) : | 1.52 |
MA(20) : | 1.1 |
| MA(100) : | 1.91  |
MA(250) : | 5.82 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 40.8 |
D(3) : | 42 |
| RSI | RSI(14): 59.5 |
|||
| 52-week | High : | 16.5 | Low : | 0.26 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BSGM ] has closed below upper band by 33.1%. Bollinger Bands are 15.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.59 - 1.6 | 1.6 - 1.61 |
| Low: | 1.28 - 1.29 | 1.29 - 1.3 |
| Close: | 1.54 - 1.55 | 1.55 - 1.57 |
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Thu, 04 Apr 2024
BioSig Engages Consulting Firm for Business Model Strategies - Yahoo Finance
Wed, 28 Feb 2024
Is BioSig Technologies Inc (BSGM) Stock a Bad Value? - InvestorsObserver
Tue, 27 Feb 2024
BioSig Technologies Announces Executive Leadership Changes - TipRanks.com - TipRanks
Tue, 20 Feb 2024
BioSig Announces Reduction of its Workforce - Yahoo Finance
Wed, 07 Feb 2024
BioSig Technologies Marks 100 Cases with Tracking Algorithm - TipRanks.com - TipRanks
Fri, 02 Feb 2024
Should You Buy BioSig Technologies Inc (BSGM) Stock on Friday? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 8e+006 (%) |
| Held by Institutions | 18.8 (%) |
| Shares Short | 895 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.815e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -51 % |
| Return on Assets (ttm) | 391.6 % |
| Return on Equity (ttm) | -603.3 % |
| Qtrly Rev. Growth | 18000 % |
| Gross Profit (p.s.) | -75.92 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.66 |
| Dividend | 0 |
| Forward Dividend | 694940 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|